Another phase III randomized trial of maintenance gefitinib vs. placebo in patients with stage III NSCLC, unselected for EGFR status, who had responded to concurrent radiochemotherapy and consolidation docetaxel demonstrated worse survival in the gefitinib arm. This evidence concerns the gene EGFR and non-small cell lung carcinoma.